Download the OCG Fact Sheet
Cancer Target Discovery and Development (CTD²) Network
The goal of the Cancer Target Discovery and Development (CTD²) Network is to accelerate the translation of genomic discoveries into new cancer treatments through innovative research. The projects of the CTD² Network bridge the gap between the enormous volumes of genomic data generated by the comprehensive molecular characterization of various cancer types and the ability to use these data for the development of human cancer therapeutics. The research is focused on high-throughput identification and characterization of potential targets for cancer therapy, such as genes and pathways, and the identification of small molecules that modulate validated cancer targets.
The CTD² Network emphasizes interactions of members with complementary and unique technical expertise in areas such as:
- Bioinformatics
- Genome-wide loss of function screening
- Targeted gain-of-function gene validations
- Mouse-based screening
- Small molecule high-throughput screening
Moving away from a one-size-fits all approach, the results from research by the CTD² Network are leading to new directions for developing treatment strategies that target specific molecular changes in a patient’s disease (i.e. precision medicine).
The laboratories of the CTD² Network in 2012–2013
| Project Title: | Systematic Development of Novel, Druggable Cancer Targets |
| Affiliation: | Translational Genomics Research Institute; Phoenix, Arizona |
| Principal Investigator: | Berens, Michael E., Ph.D. |
| Project Title: | Systems Biology of Tumor Progression and Drug Resistance |
| Affiliation: | Columbia University; New York, New York |
| Principal Investigator: | Califano, Andrea, Ph.D. |
| Project Title: | High Throughput Protein-Protein Interaction Interrogation in Cancer |
| Affiliation: | Emory University; Atlanta, Georgia |
| Principal Investigator: | Fu, Haian, Ph.D. |
| Project Title: | Functional Annotation of Cancer Genomes: TCGA, Glioblastoma and Ovarian Cancer |
| Affiliation: | Dana-Farber Cancer Institute; Boston, Massachusetts |
| Principal Investigator: | Hahn, William, M.D., Ph.D. |
| Project Title: | Bay Area Cancer Target Discovery and Development Network |
| Affiliation: | University of California San Francisco; San Francisco, California |
| Principal Investigator: | McCormick, Frank P., Ph.D. |
| Project Title: | Systems Biology of Tumor Progression and Drug Resistance |
| Affiliation: | University of Texas MD Anderson Cancer Center; Houston, Texas |
| Principal Investigator: | Mills, Gordon B., M.D., Ph.D, and Chin, Lynda, M.D. |
| Project Title: | Computational and Functional Approaches to Validating Cancer Genome Targets |
| Affiliation: | Cold Spring Harbor Laboratory; Long Island, New York |
| Principal Investigator: | Powers, Scott, Ph.D. and Lowe, Scott, Ph.D. |
| Project Title: | A Concerted Attack on Patient Specific Oncogenic Vulnerabilities in Lung Cancer |
| Affiliation: | University of Texas Southwestern Medical Center; Dallas, Texas |
| Principal Investigator: | Roth, Michael, Ph.D. and co-PIs: White, Michael, Ph.D. and Minna, John, M.D. |
| Project Title: | Targeting Causal Cancer Genes with Small Molecules |
| Affiliation: | Broad Institute; Cambridge, Massachusetts |
| Principal Investigator: | Schreiber, Stuart, Ph.D. |
View a map of the CTD² Centers 
To learn more about the Cancer Target Discovery and Development (CTD²) Network as well as access the data generated, please visit http://ctd2.nci.nih.gov/.
Back to Top
